CHRNA1

Acetylcholine receptor subunit alpha · P02708 · CHRNA1 on Sugi Atlas →

28,276 patent compounds predicted against CHRNA1, 17,691 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Radafaxine (SCHEMBL48964)	1.00	19/20
SCHEMBL240780	0.58	6/20
Bupropion (SCHEMBL38777)	1.00	5/20
Bupropion (SCHEMBL60314)	1.00	5/20
Bupropion (SCHEMBL300444)	1.00	5/20
SCHEMBL634327	1.00	5/20
Bupropion (SCHEMBL41602)	0.97	5/20
Bupropion (SCHEMBL636116)	0.97	5/20
Bupropion (SCHEMBL1237221)	0.97	5/20
Bupropion (SCHEMBL678781)	0.94	5/20
Bupropion (SCHEMBL1237589)	0.86	5/20
Bupropion (SCHEMBL1235744)	0.84	5/20
Bupropion (SCHEMBL1235748)	0.84	5/20
Bupropion (SCHEMBL1238156)	0.84	5/20
Bupropion (SCHEMBL1238245)	0.84	5/20
SCHEMBL1226857	0.74	5/20
Bupropion (SCHEMBL1237438)	0.74	5/20
Bupropion (SCHEMBL1238050)	0.74	5/20
SCHEMBL769882	0.70	5/20
SCHEMBL769683	0.68	5/20

Clinical trials — most relevant to CHRNA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)	PHASE4	COMPLETED
Galantamine for Cognition in People With Schizophrenia	PHASE4	COMPLETED
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease	PHASE4	COMPLETED
Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD	PHASE4	COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia	PHASE4	COMPLETED
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause	PHASE4	COMPLETED
Transcranial Magnetic Stimulation in Patients with Dual Disorders	PHASE3	NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3	PHASE2	COMPLETED
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response	PHASE2	COMPLETED
Nicotinic Receptors and Schizophrenia	PHASE1/PHASE2	WITHDRAWN
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])	PHASE2	COMPLETED
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease	PHASE1/PHASE2	RECRUITING
Nicotinic Receptor Augmentation of SSRI Antidepressants	PHASE2	COMPLETED
Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder	PHASE2	COMPLETED
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward	PHASE1	RECRUITING
M1 Schizophrenia PET Study	PHASE1	COMPLETED
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression	nan	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine	nan	WITHDRAWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia	nan	UNKNOWN
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia	nan	COMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia	nan	COMPLETED
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients	nan	COMPLETED
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome	nan	COMPLETED
Brain Imaging in Alzheimer's Disease	nan	COMPLETED
Nicotinic Receptor Levels After Stopping Smoking	nan	COMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy	nan	COMPLETED
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRNA1 binder may also engage these)

Protein	Name	Similarity
P04756	—	1.000	P04756 →
P02709	—	1.000	P02709 →
P25108	—	1.000	P25108 →
P02710	—	1.000	P02710 →
P02711	—	1.000	P02711 →
Q8R4G9	—	1.000	Q8R4G9 →
CHRNA6	Neuronal acetylcholine receptor subunit alpha	1.000	landscape →
Q98880	—	1.000	Q98880 →
Q5IS51	—	1.000	Q5IS51 →
P49581	—	1.000	P49581 →
P09479	—	1.000	P09479 →
P04757	—	1.000	P04757 →
P20420	—	1.000	P20420 →
CHRNB3	Neuronal acetylcholine receptor subunit beta-	1.000	landscape →
Q5IS75	—	1.000	Q5IS75 →
P05377	—	0.999	P05377 →
Q07263	—	0.999	Q07263 →
P43679	—	0.999	P43679 →
P26152	—	0.998	P26152 →
Q2MKA5	—	0.998	Q2MKA5 →
CHRNA5	Neuronal acetylcholine receptor subunit alpha	0.997	landscape →
P12391	—	0.996	P12391 →
P25162	—	0.996	P25162 →
O16926	—	0.996	O16926 →
Q8SPU7	—	0.995	Q8SPU7 →
P22456	—	0.995	P22456 →
P09481	—	0.995	P09481 →
CHRNA3	Neuronal acetylcholine receptor subunit alpha-3	0.995	landscape →
Q9N587	—	0.995	Q9N587 →
P43143	—	0.994	P43143 →